CRISPR Interference Tool Probes Antibiotic Resistance Genes

The rapid rise of antibiotic resistance represents a major global public health threat that has been estimated to endanger millions of lives and cost...

Pancreatic Cancer Immune Checkpoint Target Identified

The University of Texas MD Anderson Cancer Center-led team found that V-domain immunoglobulin suppressor of T cell activation (VISTA) is preferentially expressed at high levels in pancreatic cancer, when compared with melanoma tumors. Anti-VISTA antibodies may be an effective immunotherapeutic strategy for patients with pancreatic cancer.

Chemo Overflows Sopped Up by Vein-Lodged Sponges

Toxic spills aren’t limited to the environment. They happen inside the body, too, whenever chemotherapeutics slosh beyond the tissues they are meant to target,...

Catalent Invests $200M in Fast-Growing Biologics Manufacturing Business

Catalent says the $200 million it will spend over three years to expand drug substance manufacturing capacity and drug product fill/finish capacity in Bloomington,...

Hospitalized Patients Can Safely Receive Flu Vaccine

Hospitalized patients who received the flu vaccine had no increased risk of outpatient visits or hospital readmission within seven days of discharge.

With $8B Acquisition of Loxo, Lilly Catches Up in Cancer via...

With its planned $8 billion acquisition of Loxo Oncology, Eli Lilly signaled it is serious about catching up in cancer drug development by becoming...

Inhaled mRNA Therapy Could Be Breath of Fresh Air for Lung...

Messenger RNA has been viewed as a potential therapy for several diseases for many years. However, the biggest obstacle to this approach so far...

Jazz, Codiak to Partner on Exosome Therapeutics for Cancer in $1B+...

Jazz Pharmaceuticals will use Codiak BioSciences’ engEx™ precision engineering platform to research, develop, and commercialize exosome therapeutics for cancer through a collaboration that could...

Bristol-Myers Squibb to Acquire Celgene for $74B

Bristol-Myers Squibb (BMS) plans to acquire Celgene for approximately $74 billion, the companies said today, in a blockbuster deal designed to create a powerhouse in immunology and inflammation, cardiovascular disease—and oncology, where both companies have encountered setbacks in recent months.

Celgene Licenses Aprinoia Tau PET Tracer APN-1607 to Support Patient Selection...

Celgene has secured a nonexclusive license to use Aprinoia Therapeutics’ lead candidate, the Phase I tau positron emission tomography (PET) imaging tracer APN-1607, to...

Recently Featured

Stay Connected

557,665FansLike
45,798FollowersFollow
Scroll Up